Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Sales (2017 - 2025)

Aclaris Therapeutics has reported Return on Sales over the past 9 years, most recently at 16.29% for Q4 2025.

  • Quarterly results put Return on Sales at 16.29% for Q4 2025, down 570.0% from a year ago — trailing twelve months through Dec 2025 was 8.78% (down 163.0% YoY), and the annual figure for FY2025 was 8.78%, down 173.0%.
  • Return on Sales for Q4 2025 was 16.29% at Aclaris Therapeutics, down from 4.65% in the prior quarter.
  • Over the last five years, Return on Sales for ACRS hit a ceiling of 0.11% in Q4 2023 and a floor of 17.02% in Q2 2023.
  • Median Return on Sales over the past 5 years was 10.23% (2021), compared with a mean of 9.09%.
  • Biggest five-year swings in Return on Sales: tumbled -1587bps in 2021 and later skyrocketed 1305bps in 2024.
  • Aclaris Therapeutics' Return on Sales stood at 15.25% in 2021, then skyrocketed by 75bps to 3.75% in 2022, then skyrocketed by 97bps to 0.11% in 2023, then crashed by -9917bps to 10.59% in 2024, then crashed by -54bps to 16.29% in 2025.
  • The last three reported values for Return on Sales were 16.29% (Q4 2025), 4.65% (Q3 2025), and 9.22% (Q2 2025) per Business Quant data.